Pankaj Qasba Deepti Qasba from Glenelg, MD, age 68

view source

Location:

14234 Meadow Lake Dr, Glenelg, MD 21737

Industry:

Research

Work:

National Institutes of Health
Program Director, Blood Diseases Branch

Skills:

Leadership
Cvs
Magnetics

Interests:

Investing
Sweepstakes
Electronics
Home Improvement
Travel
Home Decoration

view source

Location:

Glenelg, MD

Industry:

Health, Wellness And Fitness

Work:

DHHS
PD

view source

Position:

Program Director at NIH

Location:

Baltimore, Maryland Area

Industry:

Health, Wellness and Fitness

Work:

NIH
Program Director

Production Of Megakaryocytes By The Use Of Human Mesenchymal Stem Cells
view source
US Patent:

7153500, Dec 26, 2006
Filed:

Feb 9, 2001
Appl. No.:

09/780653
Inventors:

Pankaj Qasba - Columbia MD, US
Mark A. Thiede - Forest Hill MD, US
Assignee:

Osiris Therapeutics - Baltimore MD
International Classification:

A01N 63/00
A01N 65/00
C12N 5/00
US Classification:

424 9321, 435325, 424 931
Abstract:

The present invention is directed to hematopoietic progenitor cells isolated from a tissue specimen, such as marrow cells or peripheral blood, and to the method of co-culturing isolated hematopoietic progenitor cells with human mesenchymal stem cells to induce megakaryocyte differentiation and platelet production. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate blood disorders.

Production Of Megakaryocytes By The Use Of Human Mesenchymal Stem Cells
view source
US Patent:

62251198, May 1, 2001
Filed:

May 21, 1999
Appl. No.:

9/316797
Inventors:

Pankaj Qasba - Columbia MD
Mark A. Thiede - Forest Hill MD
Assignee:

Osiris Therapeutics, Inc. - Baltimore MD
International Classification:

C12N 500
C12N 508
C12N 506
C12N 510
A01N 6300
US Classification:

435373
Abstract:

The present invention is directed to hematopoietic progenitor cells isolated from a tissue specimen, such as marrow cells or peripheral blood, and to the method of co-culturing isolated hematopoietic progenitor cells with human mesenchymal stem cells to induce megakaryocyte differentiation and platelet production. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate blood disorders.